1-(5-chloro-2-methylphenyl)-3-ethylthiourea | 19384-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(5-chloro-2-methylphenyl)-3-ethylthiourea
• 英文别名: N-Ethyl-N'-(5-chlor-2-methylphenyl)-thioharnstoff；N-(5-chloro-2-methylphenyl)-N '-ethylthiourea；N-(5-chloro-2-methylphenyl)-N'-ethylthiourea
• CAS: 19384-12-4
• 化学式: C₁₀H₁₃ClN₂S
• mdl: MFCD04480059
• 分子量: 228.746
• InChiKey: ZUOCSNWZNHROCV-UHFFFAOYSA-N

物化性质

• 熔点：
  128-129 °C
• 沸点：
  306.1±52.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  草酰氯单乙酯 、 1-(5-chloro-2-methylphenyl)-3-ethylthiourea 在 乙酸乙酯 、 碳酸氢钠 、 magnesium sulfate 、 乙醚 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以to give 1-(5-Chloro-2-methylphenyl)-3-ethyl-2-thioxo-4,5-imidazolidinedione (14.1 g), m.p. 173–174° C的产率得到1-(5-Chloro-2-methylphenyl)-3-ethyl-2-thioxo-4,5-imidazolidinedione
  参考文献：
  名称：

  1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis

  摘要：

  提供了式I的抗动脉粥样硬化化合物： 其中： R为低碳基，烯基，炔基或-O-(CH2)n-COOR′； R′为低碳基； n为1-3的整数； Ar为苯基，或带有卤素，低碳基，烯基，炔基，烷氧基，全氟烷基，全氟烷氧基或烷基硫基的取代苯基； 以及其药学上可接受的盐。

  公开号：

  US20030119889A1
• 作为产物：
  描述：

  5-氯-2-甲基异硫氰酸苯酯 、 乙胺 在 乙胺 、 氮气 、 水 作用下， 反应 18.0h， 以to give N-(5-chloro-2-methylphenyl)-N ′-ethylthiourea (18.9 g)的产率得到1-(5-chloro-2-methylphenyl)-3-ethylthiourea
  参考文献：
  名称：

  1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis

  摘要：

  提供了式I的抗动脉粥样硬化化合物： 其中： R为低碳基，烯基，炔基或-O-(CH2)n-COOR′； R′为低碳基； n为1-3的整数； Ar为苯基，或带有卤素，低碳基，烯基，炔基，烷氧基，全氟烷基，全氟烷氧基或烷基硫基的取代苯基； 以及其药学上可接受的盐。

  公开号：

  US20030119889A1

文献信息

• 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis
  申请人：Wyeth

  公开号：US20030119889A1

  公开（公告）日：2003-06-26

  Antiatherosclerotic compounds of Formula I are provided: 1 wherein: R is lower alkyl, alkenyl, alkynyl, or —O—(CH 2 ) n —COOR′; R′ is lower alkyl; n is an integer of 1-3; Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.

  提供了化学式I的抗动脉粥样硬化化合物： 其中： R为较低的烷基，烯基，炔基，或—O—(CH 2 ) n —COOR′; R′为较低的烷基; n为1-3的整数; Ar为苯基，或苯基上取代一个或多个卤素，较低的烷基，烯基，炔基，烷氧基，全氟烷基，全氟烷氧基，或烷基硫基;以及 其药用可接受盐。
• 1,3-disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis
  申请人：Wyeth

  公开号：US07135492B2

  公开（公告）日：2006-11-14

  Antiatherosclerotic compounds of Formula I are provided: wherein: R is lower alkyl, alkenyl, alkynyl, or —O—(CH2)n—COOR′; R′ is lower alkyl; n is an integer of 1–3; Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.

  提供了公式I的抗动脉粥样硬化化合物： 其中： R是低烷基，烯基，炔基或—O—（CH2）n—COOR′; R′是低烷基; n为1-3的整数; Ar是苯基，或苯基上带有卤素，低烷基，烯基，炔基，烷氧基，全氟烷基，全氟烷氧基或烷基硫基;以及其药学上可接受的盐。
• US7135492B2
  申请人：——

  公开号：US7135492B2

  公开（公告）日：2006-11-14
• Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties
  作者：Hassan Elokdah、Theodore S. Sulkowski、Magid Abou-Gharbia、John A. Butera、Sie-Yearl Chai、Geraldine R. McFarlane、Mar-Lee McKean、John L. Babiak、Steven J. Adelman、Elaine M. Quinet

  DOI：10.1021/jm030219z

  日期：2004.1.1

  A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of I directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical. studies.
• Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents
  作者：Gary M. Coppola、Robert E. Damon、J. Bruce Eskesen、Dennis S. France、James R. Paterniti

  DOI：10.1016/j.bmcl.2005.09.034

  日期：2006.1

  A series of 1-alkyl-3-phenylthiourea analogues were prepared and evaluated as HDL- and Apo A-I-elevating and triglyceride-lowering agents. Several derivatives were superior to gemfibrozil (1). The optimal analogue 8d (HDL376) was shown to raise HDL cholesterol in the rat, hamster, dog, and monkey models. (c) 2005 Elsevier Ltd. All rights reserved.